NCT07817251ClinicalTrials.gov
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes
En resumen
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in…
Fase 3210 participantes buscados40 centros1 país
Categorías
Registrado en 1 registro
- ClinicalTrials.govNCT07817251Abrir este registro en ClinicalTrials.govSincronizado hace 2 meses
Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.
La información del ensayo se muestra tal como la publicó el registro, en su idioma original.
¿Le interesa este estudio?
Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-09-14; recorded start 2026-09-16
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 351 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 40 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 210 participants (target), run at 40 sites.
How this score is built
- Enrolment22/40
210 participants (target)
- Site count19/25
40 sites
- Country count0/15
Single country
- Planned duration4/10
Planned over about 10 months
- Sponsor scale9/10
Novo Nordisk A/S has led 339 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Resumen
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.
Afecciones
- Diabetes Mellitus, Type 2
Elegibilidad
| Sexo | Todos |
|---|---|
| Edades | 18 Years – Sin máximo |
| Voluntarios sanos | No |
Elegibilidad tal como figura en el registro
Elegibilidad en frases sencillas
Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.
Diseño del estudio
| Tipo de estudio | De intervención |
|---|---|
| Fase | Fase 3 |
| Asignación | Aleatorizado |
| Modelo de intervención | PARALLEL |
| Propósito principal | TREATMENT |
| Enmascaramiento | QUADRUPLE (4) |
| Inscripción | 210 participantes buscados |
Patrocinador y colaboradores
- Novo Nordisk A/S Patrocinador
Grupos e intervenciones
- CagriSema dose 1EXPERIMENTAL
Participants previously treated with once-weekly semaglutide subcutaneously (s.c.) will switch to once-weekly CagriSema dose 1.
- CagriSema dose 2EXPERIMENTAL
Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 2, followed by dose 1.
- CagriSema dose 3EXPERIMENTAL
Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.
Intervenciones
- Fármaco CagriSema
CagriSema will be administered s.c. once weekly.
Variables de resultado
Variable de resultado principal
Number of treatment emergent adverse events (TEAEs)
Measured as count of events.
Plazo From baseline (Week 0) to end of treatment (Week 16)
Variable de resultado secundaria
Number of TEAEs
Measured as count of events.
Plazo From baseline (Week 0) to end of study (Week 22)
Variable de resultado secundaria
Number of TEAEs
Measured as count of events.
Plazo From baseline (Week 0) to Week 8
Variable de resultado secundaria
Number of clinically significant hypoglycaemic episodes (level 2) (less than [<] 3.0 millimoles per liter [mmol/L] (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose [BG] meter)
Measured as count of episodes.
Plazo From baseline (Week 0) to end of study (Week 22)
Variable de resultado secundaria
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Measured as count of episodes.
Plazo From baseline (Week 0) to end of study (Week 22)
Variable de resultado secundaria
Number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL), confirmed by BG meter)
Measured as count of episodes.
Plazo From baseline (Week 0) to Week 8
Variable de resultado secundaria
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Measured as count of episodes.
Plazo From baseline (Week 0) to Week 8
Variable de resultado secundaria
Number of participants who discontinued due to gastrointestinal (GI) adverse events (AEs)
Measured as count of participants.
Plazo From baseline (Week 0) to end of treatment (Week 16)
Fechas
| Fecha de inicio | 16 de septiembre de 2026 (real) |
|---|---|
| Finalización principal | 9 de junio de 2027 (estimada) |
| Finalización | 21 de julio de 2027 (estimada) |
| Primera publicación | 14 de septiembre de 2026 (real) |
| Última actualización | 30 de septiembre de 2026 |
| Resultados publicados | No indicado en el registro |
| Estado verificado por última vez | septiembre de 2026 |
Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.
Ubicaciones
37 centros están en reclutamiento
United States
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Albuquerque Clinical Trials Inc. | Albuquerque | New Mexico | En reclutamiento |
| Amarillo Med Spec LLP | Amarillo | Texas | En reclutamiento |
| Texas Diabetes & Endocrinology | Austin | Texas | En reclutamiento |
| Northern Pines Hlth Ctr, PC | Buckley | Michigan | En reclutamiento |
| North Texas Endocrine Center | Dallas | Texas | En reclutamiento |
| Northeast Research Institute | Fleming Island | Florida | En reclutamiento |
| Diabetes and Thyroid Center of Fort Worth | Fort Worth | Texas | En reclutamiento |
| Ark Clinical Research | Fountain Valley | California | En reclutamiento |
| Gilbert Center For Family Medicine | Gilbert | Arizona | En reclutamiento |
| Thrive Clinical Research Group | Glendora | California | En reclutamiento |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | En reclutamiento |
| AGA Clinical Trial | Hialeah | Florida | En reclutamiento |
| East West Med Res Inst | Honolulu | Hawaii | En reclutamiento |
| JCCT- Juno NW Houston | Houston | Texas | En reclutamiento |
| Sante Clinical Research | Kerrville | Texas | En reclutamiento |
| Scripps Whittier Diabetes Inst | La Jolla | California | En reclutamiento |
| Palm Research Center Inc-Vegas | Las Vegas | Nevada | En reclutamiento |
| DCOL Ctr for Clin Res | Longview | Texas | En reclutamiento |
| Downtown LA Res Ctr. Inc. | Los Angeles | California | En reclutamiento |
| Advanced Medical Research | Maumee | Ohio | Aún no recluta |
| Adult Medicine of Lake County, Inc | Mt. Dora | Florida | En reclutamiento |
| Clinical Research Associates | Nashville | Tennessee | En reclutamiento |
| Tidewater Physicians Multispecialty Group | Newport News | Virginia | En reclutamiento |
| Alliance for Multispecialty Research | Newton | Kansas | En reclutamiento |
| North Hills Medical Research Inc | North Richland Hills | Texas | En reclutamiento |
| Valley Clinical Trials, Inc. | Northridge | California | En reclutamiento |
| Optimal Research Sites | Orange City | Florida | En reclutamiento |
| Dream Team Clinical Research | Pomona | California | En reclutamiento |
| Clinical Trials Research_Sacramento | Sacramento | California | En reclutamiento |
| J.Lewis Research Inc | Salt Lake City | Utah | En reclutamiento |
| NE Clin Res of San Antonio | San Antonio | Texas | Aún no recluta |
| Linda Vista Health Care Ctr | San Diego | California | En reclutamiento |
| Diabetes & Endo Treatment Spec | Sandy City | Utah | Aún no recluta |
| Endeavor Health | Skokie | Illinois | En reclutamiento |
| Chrysalis Clinical Research | St. George | Utah | En reclutamiento |
| Cotton O'Neil Diabetes & Endocrinology | Topeka | Kansas | En reclutamiento |
| Chase Medical Research LLC | Waterbury | Connecticut | En reclutamiento |
| Iowa Diabetes & Endo Res Ctr | West Des Moines | Iowa | En reclutamiento |
| Metabolic Research Institute Inc | West Palm Beach | Florida | En reclutamiento |
| Accellacare Wilmington | Wilmington | North Carolina | En reclutamiento |
Documentos del estudio
No hay documentos enlazados en este registro.
Cambios a lo largo del tiempo
- 30 de septiembre de 2026
Estado modificado
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 30 de septiembre de 2026
Reclutamiento abierto
Recruitment opened
NOT_YET_RECRUITINGRECRUITING